BTG (LON:BTG) touted results today from a one-year follow-up of pulmonary embolism patients who received the company’s Ekos therapy in its Optalyse PE trial.
Researchers studied the 12-month outcomes of 101 patients who were treated over a shorter period and with smaller doses of thrombolytic drugs compared to the current standard. Pulmonary embolism patients treated with BTG’s Ekos device and anti-coagulation drugs received therapy in as little as two hours with a tissue plasminogen activator dose as low as 8 mg, the company reported.
Get the full story at our sister site, Drug Delivery Business News.
The post BTG touts one-year follow-up data for Ekos pulmonary embolism therapy appeared first on MassDevice.
from MassDevice http://ift.tt/2nNa7dy
Cap comentari:
Publica un comentari a l'entrada